title: Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass.
abstract: OBJECTIVE
  The aim was to determine whether the administration of aprotinin can cause deleterious effects on renal function in cardiac surgery with cardiopulmonary bypass (CPB).
  
  
  METHODS
  Sixty consecutive patients with normal preoperative renal function undergoing elective coronary artery bypass surgery with CPB using the same anaesthetic; CPB and surgical protocols were randomized into three groups. Patients received placebo (Group 1), low-dose aprotinin (Group 2) or high-dose aprotinin (Group 3). Renal parameters measured were plasma creatinine, alpha1-microglobulin and beta-glucosaminidase (beta-NAG) excretion. Measurements were performed before surgery, during CPB and 24 and 72 h, and 7 and 40 days postoperatively.
  
  
  RESULTS
  In the three groups, alpha1-microglobulin and beta-NAG excretions significantly increased during CPB, at 24 and 72 h, and 7 days postoperatively (P < 0.05) and had returned to preoperative levels at postoperative day 40. Plasma creatinine levels were within normal values at times recorded. In Groups 2 and 3, alpha1-microglobulin excretion during CPB was significantly higher than in Group 1 (P < 0.001), and 24h after surgery it still remained significantly higher in Group 3 compared to Groups 1 and 2 (P < 0.05).
  
  
  CONCLUSIONS
  Aprotinin caused a significant increase in alpha1-microglobulin excretion but not in beta-NAG excretion during CPB, which may be interpreted as a greater renal tubular overload without tubular damage. This effect persisted for 24 h after surgery when high-dose aprotinin doses had been administered. Creatinine plasma levels were not sensitive to detect these prolonged renal effects in our study.
authors.affiliation: University of Barcelona, Hospital Clinic, Department of Anesthesiology, Barcelona, Spain. afauli@clinic.ub.es
authors.forename: A
authors.initials: A
authors.lastname: Faulí
authors.forename: C
authors.initials: C
authors.lastname: Gomar
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: L
authors.initials: L
authors.lastname: Alvarez
authors.forename: A M
authors.initials: AM
authors.lastname: Manig
authors.forename: P
authors.initials: P
authors.lastname: Matute
mesh_terms: D000118:Acetylglucosaminidase / Q000652:urine; D000510:Alpha-Globulins / Q000652:urine; D007611:Aprotinin / Q000008:administration & dosage*; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010919:Placebos; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000652:urine; D014556:Urine
chemical_list: D000510:Alpha-Globulins; D006490:Hemostatics; D010919:Placebos; D011480:Protease Inhibitors; C016001:alpha-1-microglobulin; D007611:Aprotinin; D003404:Creatinine; D000118:Acetylglucosaminidase